Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM INTENSOL versus VERSED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZEPAM INTENSOL versus VERSED.
LORAZEPAM INTENSOL vs VERSED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.
0.5-2 mg orally every 6-8 hours as needed. Maximum 4 mg/day.
IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in elderly (15-20 hours) and patients with hepatic impairment (up to 30-40 hours).
Terminal elimination half-life: 1.8–2.5 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity (up to 8 hours), hepatic cirrhosis (up to 20 hours), and critically ill patients.
Renal excretion of glucuronide conjugates; <1% unchanged drug excreted renally. Fecal elimination accounts for approximately 10% of administered dose.
Renal: ~1% unchanged; Hepatic metabolism to glucuronide conjugates and 1-hydroxymidazolam, with subsequent renal elimination of metabolites. Fecal excretion is minimal (<2%).
Category D/X
Category C
Benzodiazepine
Benzodiazepine